Happy New Year?

  Happy New Year? January looms as a crucial month for the near-term prospects of Australian biotech, Mesoblast.  December saw the company’s treatments fail to meet primary endpoints in both its Chronic Heart Failure (CHF) and COVID-19 Acute Respiratory Distress Syndrome (C19 ARDS) phase 3 trials.  These failures, along with Read more…